Trial Profile
A prospective, multi-centre study of Icatibant for the treatment of acute attacks in patients with hereditary angiodema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2016
Price :
$35
*
At a glance
- Drugs Icatibant (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- 18 Mar 2016 New trial record
- 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology